I. Mammakarzinom

AGO-Leitlinien 2018 der Kommission Mamma der AGO der DGGG; https://www.ago-online.de/fileadmin/downloads/leitlinien/mamma/2018-03/Gesamt_deutsch/Alle_aktuellen_Empfehlungen_2018.pdf

Allen R.J., Treece P.: Deep inferior epigastric perforator flap for breast reconstruction. Ann Plast Surg 1994; 32: 32–38

Allred D.C., Anderson S.J., Paik S. et al.: Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP Protocol B-24. J Clin Oncol 2012. doi: 10.1200/JCO.2010.34.0141

Alsaker M.D., Janszky I., Opdahl S., Vatten L.J., Romundstad P.R.: Weight change in adulthood and risk of postmenopausal breast cancer: the HUNT study of Norway. Br J Cancer 2013; 109 (5): 1310–7

Anne N., Pallapothu R.: Lymphoma of the breast: a mimic of inflammatory breast cancer. World J Surg Oncol 2011; 9: 125. doi: 10.1186/1477-7819-9-125

AWMF – S3-Leitlinie für die Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms; Version 4.1 – September 2018, AWMF-Registernummer: 032-045OL; www.awmf.org/uploads/tx_szleitlinien/032-045OLl_S3_Mammakarzinom_2018-09.pdf

Barrio A.V., Clark B.D., Goldberg J.I. et al.: Clinicopathologic features and long-term outcomes of 293 phyllodes tumors of the breast. Ann Surg Oncol 2007; 14: 2961–2970

Barton S.R., Smith I.E., Kirby A.M., Ashley S., Walsh G., Parton M.: The role of ipsilateral breast radiotherapy in management of occult primary breast cancer presenting as axillary lymphadenopathy. Eur J Cancer 2011; 47: 2099–2106. doi: 10.1016/j.ejca.2011.05.010

Baselga J. et al.: PIK3CA Status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-reistant HR+/Her-2– advanced breast cancer (BC): First results from the randomized, phase III BELLE-2 trial. Lancet Oncol; 2017; 18: 904–16

Behranwala K.A., Nasiri N., Abdullah N., Trott P.A., Gui G.P.: Squamous cell carcinoma of the breast: clinico-pathologic implications and outcome. Eur J Surg Oncol 2003; 29 (4): 386

Boughey J.C., Bedrosian I., Meric-Bernstam F. et al.: Comparitive analysis of sentinel lymph node operation in male and female breast cancer patients. J Am Coll Surg 2006; 203: 475–480

Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490 (7418): 61

Colditz G.A., Frazier A.L.: Models of breast cancer show that risk is set by events of early life: prevention efforts must shift focus. Cancer Epidemiol Biomarkers Prev 1995; 4 (5): 567

Colditz G.A., Rosner B.: Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses’ Health Study. Am J Epidemiol 2000; 152 (10): 950

Confavreux C., Lurkin A., Mitton N. et al.: Sarcomas and malignant phyllodes tumours of the breas–a retrospective study. Eur J Cancer 2006; 42: 2715–2721

Cristofanilli M. et al.: Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor positive, Her2 -negative metastatic breast cancer that progressed on previous enocrine therapy (PALOMA-3): final analysis of the multicentre, double blind, phase 3 randomised controlled trial. Lancet Oncol 2016; 17: 425–39

Dawood S., Merajver S.D., Viens P. et al.: International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol 2011; 22: 515–523. doi:10.1093/annonc/mdq345

Dayhim F., Wilkins E.G.: The impact of Pfannenstiel scars on TRAM flap complications. Ann Plast Surg 2004; 53: 432–435

Deurloo E.E., Sriram J.D., Teertstra H.J. et al.: MRI of the breast in patients with DCIS to exclude the presence of invasive disease. Eur Radiol 2012. doi:10.1007/s00330-012-2394-5

Dominici L.S., Lester S., Liao G.S. et al.: Current surgical approach to Paget’s disease. Am J Surg 2011. doi:10.1016/j.amjsurg.2011.07.010

Dubsky P., Brase J.C., Jakesz R. et al.: The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2– breast cancer patients. Br J Cancer 2013; 109 (12): 2959–64

Emaus M.J. et al.: Weight change in middle adulthood and breast cancer risk in the EPIC-PANACEA study. Int J Cancer 2014; 135 (12): 2887–99

Finn R.S. et al.: Palbociclib and letrozole in advanced breast cancer. N Eng J Med 2016; 375: 1925–36

Finn R.S. et al.: The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of estrogen receptor positive, Her-2 negative , advanced breast cancer (PALOMA-1/TRIO-18): a randomizesed phase 2 study. Lancet oncol 2015; 16: 25–35

Fisher B., Dignam J., Wolmark N. et al.: Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999; 353: 1993–2000. doi: 10.1016/S0140-6736(99)05036-9

Gentilini O., Cremonesi M., Toesca A. et al.: Sentinel lymph node biopsy in pregnant patients with breast cancer. Eur J Nucl Med Imaging 2010; 37: 78–83

German G., Steinau H.U.: Breast reconstruction with the extended latissimus dorsi flap. Plast Reconstr Surg 1996; 97: 519–526

Giuliano A.E., Hunt K.K., Ballman K.V. et al.: Axillary dissection vs. no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011; 305: 569–575. doi: 10.1001/jama.2011.90

Goetz M.P. et al.: MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol 2017; 35 (32): 3638–3646; doi: 10.1200/JCO.2017.75.6155

Gradishar W.J., Anderson B.O., Balassanian R., Blair S.L., Burstein H.J., Cyr A., Elias A.D., Farrar W.B., Forero A., Giordano S.H., Goetz M., Goldstein L.J., Hudis C.A., Isakoff S.J., Marcom P.K., Mayer I.A., McCormick B., Moran M., Patel S.A., Pierce L.J., Reed E.C., Salerno K.E., Schwartzberg L.S., Smith K.L., Smith M.L., Soliman H., Somlo G., Telli M., Ward J.H., Shead D.A., Kumar R.: Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. Compr Canc Netw 2016; 14 (3): 324–54

Gram I.T., Park S.Y., Kolonel L.N., Maskarinec G., Wilkens L.R., Henderson B.E., Le Marchand L.: Smoking and Risk of Breast Cancer in a Racially/ Ethnically Diverse Population of Mainly Women Who Do Not Drink Alcohol: The MEC Study. Am J Epidemiol 2015; 182 (11): 917–25

Hahn K. et al.: Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer 2006; 107: 1219–1226

Harris L.N., Ismaila N., McShane L.M.: Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016; 34 (10): 1134

Hayes D.F.: Follow up of patients with early breast cancer. N Engl J Med 2007; 356: 2505–13

Heller L., Feledy J.A. Chang D.W.: Strategies and options for free TRAM flap breast reconstruction in patients with midline abdominal scars. Plast Reconstr Surg 2005; 116: 753–759

Hennessy B.T., Krishnamurthy S., Giordano S., Buchholz T.A., Kau S.W., Duan Z., Valero V., Hortobagyi G.N.: Squamous cell carcinoma of the breast. J Clin Oncol 2005; 23 (31): 7827

Holland R., Peterse J.L., Millis R.R. et al., Semin Diagn Pathol 1994; 11: 167

Holmström H.: The free abdominoplasty flap and its use in breast reconstruction: an experimental study and clinical case report. Scand J Plast Reconstr Surg 1979; 13: 423–437

Hortbagyi G.N. et al.: Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 2016; 375: 1738–48

Houssami N., Ciatto S., Turner R.M., Cody H.S. III., Macaskill P.: Preoperative ultrasound-guided needle biopsy of axillary nodes in invasive breast cancer: meta-analysis of its accuracy and utility in staging the axilla. Ann Surg 2011; 254 (2): 243–251. doi:10.1097/ SLA.0b013e31821f1564

Howell A. et al.: Fulvestrant, formerly ICI 182.780 is as effective as anastrazole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002; 20 (16): 3396– 403

Hubalek M., Bartsch R., Gnant M., Kapp K. S., Lang A., Lax S., Lukas P., Neunteufel W., Pristauz G., Reitsamer R., Sandbichler P., Schrenk P., Singer C., Tamussino K., Tschmelitsch J., Zeimet A. G., Marth C.: Axillary Dissection in the Case of Positive Sentinel Lymph Nodes: Results of the Innsbruck Consensus Conference. Geburtsh Frauenheilk 2012; 72: 293– 298

Hwang E.S., Kinkel K., Esserman L.J., Lu Y., Weidner N., Hylton N.M.: Magnetic resonance imaging in patients diagnosed with ductal carcinomain- situ: value in the diagnosis of residual disease, occult invasion, and multicentricity. Ann Surg Oncol 2003; 10: 381–388

Jaiyesimi I.A., Buzdar A.U., Hortobagyi G.: Inflammatory breast cancer: a review. J Clin Oncol 1992; 10 (6): 1014

Jansen M.P., Sieuwerts A.M., Look M.P. et al.: HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study. J Clin Oncol 2007; 25 (6): 662

Kaur P., Kiluk J.V., Meade T. et al.: Sentinel lymph node biopsy in patients with previous ipsilateral complete axillary lymph node dissection. Ann Surg Oncol 2011; 18: 727–732. doi: 10.1245/s10434-010-1120-2

Khatcheressian J.L., Hurley P., Bantug E., Esserman L.J., Grunfeld E., Halberg F., Hantel A., Henry N.L., Muss H.B., Smith T.J., Vogel V.G., Wolff A.C., Somerfield M.R., Davidson N.E.; American Society of Clinical Oncology: Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013; 31 (7): 961–5. doi: 10.1200/JCO.2012.45.9859

Kiluk J.V., Lee M.C., Park C.K. et al.: Male breast cancer: management and follow-up recommendations. Breast J 2011; 17: 503–509

Lagios M.D., Margolin F.R., Westdahl P.R., Rose M.R.: Cancer 1989; 63: 618

Liu G.F., Yang Q., Haffty B.G., Moran M.S.: Clinical-pathologic features and long-term outcomes of tubular carcinoma of the breast compared with invasive ductal carcinoma treated with breast conservation therapy. Int J Radiat Oncol Biol Phys 2009; 75 (5): 1304

Lovrics P.J., Goldsmith C.H., Hodgson N. et al.: A multicentered, randomized, controlled trial comparing radioguided seed localization to standard wire localization for nonpalpable, invasive and in situ breast carcinomas. Ann Surg Oncol 2011; 18: 3407–3414. doi:10.1245/ s10434-011-1699-y

Lu W..L, Jansen L., Post W.J., Bonnema J., Van de Velde J.C., De Bock G.H.: Impact on survival of early detection of isolated breast recurrences after the primary treatment for breast cancer: a meta-analysis. Breast Cancer Res Treat 2009; 114 (3): 403–12

Mamounas E.P., Brown A., Anderson S., Smith R., Julian T., Miller B. et al.: Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2005; 23: 2694–2702. doi: 10.1200/ JCO.2005.05.188

McCormack V.A., dos Santos Silva I.: Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006; 15 (6): 1159

McCraw J., Papp C.: The fleur-de-lis autogenous Latissimus dorsi myocutaneous flap breast reconstruction. Presented before the Annual Meeting of the American Association of Plastic Surgeons 1989, Scottsdale

Megdal S.P., Kroenke C.H., Laden F., Pukkala E., Schernhammer E.S.: Night work and breast cancer risk: a systematic review and meta-analysis. Eur J Cancer 2005; 41 (13): 2023

Mir O. et al.: Taxanes during pregnancy a systematic review. Ann Oncol 2010; 21 (2): 425–426

Moran M.S, et al.: Society of Surgical Oncology-American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer. J Clin Oncol 2014; 32: 1507–15

Morrow M. et al.: Society of Surgical Oncology – American Society for Radiation Oncology – American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ. J Clin Oncol 2016

Murthy V., Chamberlain R.S.: Defining a place for nipple sparing mastectomy in modern breast care: an evidence based review. Breast J 2012. doi: 10.1111/j.1524-4741.2011.01220.x

Narod S.A., Iqbal J., Giannakeas V. et al.: Breast cancer mortality after a diagnosis of ductal carcinomain situ. JAMA Oncol 2015; 1: 888–896

NCCN: Breast cancer Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2003; 1: 148–88

Parker J.S., Mullins M., Cheang M.C. et al.: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27 (8): 1160

Perou C.M., Sørlie T., Eisen M.B. et al.: Molecular portraits of human breast tumours. Nature 2000; 406 (6797): 747

- Petru E., Jonat R., Fink D., Köchli O. (Hrsg.): Praxisbuch Gynäkologische Onkologie, 4. Auflage, Springer, Heidelberg, 2014

Rojas M.P., Telaro E., Russo A., Moschetti I., Coe L., Fossati R., Palli D., del Roselli T.M., Liberati A.: Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev 2005; (1): CD001768

Romics L. Jr., Chew B.K., Weiler-Mithoff E. et al.: Ten-year follow-up of skin-sparing mastectomy followed by immediate breast reconstruction. Br J Surg 2012. doi: 10.1002/bjs.8704

Rosselli Del Turco M., Palli D., Cariddi A., Ciatto S., Pacini P., Distante V.: Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. JAMA 1994; 271 (20): 1593–7

Rugo H.S., Rumble R.B., Macrae E., Barton D.L., Connolly H.K., Dickler M.N., Fallowfield L., Fowble B., Ingle J.N., Jahanzeb M., Johnston S.R.D., Korde L.A., Khatcheressian J.L., Mehta R.S., Muss H.B., Burstein H.J.: Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. J Clin Oncol 2016; 34 (25): 3069–103

Sher T., Hennessy B.T., Valero V. et al.: Primary angiosarcomas of the breast. Cancer 2007; 110: 173–178

Siegel R.L., Miller K.D., Jemal A.: Cancer statistics, 2016. CA Cancer J Clin. 2016; 66 (1): 7

Silverstein M.J., Poller D.N., Waisman J.R. et al., Lancet 1995; 345: 1154

Silverstein M.J., Waisman J.R., Gamagami P., Gierson E.D., Colburn W.J., Rosser R.J., Gordon P.S., Lewinsky B.S., Fingerhut A.: Intraductal carcinoma of the breast (208 cases). Clinical factors influencing treatment choice. Cancer 1990; 66 (1): 102

Slamon D.J. et al.: Phase III randomized study of ribociclib and fulvestrant in hormone-receptor positive, HER2 neu negative advanced breast cancer MONALEESA-3. J Clin Oncol 2018; 36 (24): 2465–2472; doi: 10.1200/JCO 2018.78.9909

Sledge G.W. jr. et al.: MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2– Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol 2017; 35 (25): 2875–2884; doi: 10.1200/JCO.2017.73.7585

Smith T.J. et al.: 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24 (19): 3187–3205

Sparano J.A., Gray R.J., Makower D.F. et al.: Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 2015; 373 (21): 2005

Statistik Austria: http://www.statistik.at/web_de/statistiken/menschen_und_gesellschaft/gesundheit/krebserkrankungen/brust/index.html; letzte Änderung am 28. 1. 2016

Swain S.M., Jeong J.H., Geyer C.E. Jr, et al.: Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 2010; 362 (22): 2053

Thurman S.A., Schnitt S.J., Connolly J.L., Gelman R., Silver B., Harris J.R., Recht A.: Outcome after breast-conserving therapy for patients with stage I or II mucinous, medullary, or tubular breast carcinoma. Int J Radiat Oncol Biol Phys 2004; 59 (1): 152

Van Zee K.J., Subhedar P., Olcese C., Patil S,. Morrow M.: Relationship between margin width and recurrence of ductal carcinoma in situ: analysis of 2996 women treated with breast-conserving surgery for 30 years. Ann Surg 2015; 262 (4): 623–31

Varadarajan R., Edge S.B., Yu J., Watroba N., Janarthanan B.R.: Prognosis of occult breast carcinoma presenting as isolated axillary nodal metastasis. Oncology 2006; 71: 456–459. doi: 10.1159/000107111

Vashi R., Hooley R., Butler R., Geisel J., Philpotts L.: Breast Imaging of the Pregnant and Lactating Patient: Imaging Modalities and Pregnancy- Associated Breast Cancer. Am J Roentgen 2013; 200: 321–328

Weaver D.L., Ashikaga T., Krag D.N. et al.: Effect of Occult Metastases on Survival in Node-Negative Breast Cancer. New Engl J Med 2011; 364: 412–421. doi: 10.1056/Nejmoa1008108

Wilcken N. at al.: Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev 2003; CD002747

Wittekind et al.: TNM: Klassifikation maligner Tumoren. 7. Auflage. Wiley- VCH Verlag, Weinheim 2010; 3. korrigierter Nachdruck 2011

Wolf I., Sadetzki S., Catane R., Karasik A., Kaufman B.: Diabetes mellitus and breast cancer. Lancet Oncol 2005; 6 (2): 103

Yardley D et al.: Everolimus plus exemestane in postmenopausal patients with HR+ breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther 2013; 30: 870–884